Supplemental NDA Submitted for Renal Cell Carcinoma Combination Treatment
In an August press release, the submission of a supplemental New Drug Application (sNDA) to the FDA for cabozantinib (Cabometyx) in combination with nivolumab (Opdivo) for the treatment of patients with advanced renal cell carcinoma (RCC) was announced. The sNDA was based on the results of the phase III CheckMate-9ER trial evaluating cabozantinib in combination with nivolumab compared with sunitinib. Read more. 

Darzalex-Based Combination Approved for Adults with Relapsed/ Refractory Multiple Myeloma
On August 20, 2020, the FDA announced the approval of the triple regimen of daratumumab, an anti-CD38 therapy, in combination with the use of carfilzomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have been treated with one to three prior therapies. The efficacy of carfilzomib and daratumumab with dexamethasone was assessed in two clinical trials. Read more.

Azacitidine and Venetoclax May Benefit Older AML Patients 
In a recent article in the New England Journal of Medicine, results indicate that among older patients with acute myeloid leukemia (AML) who have not received any prior therapy and were ineligible for standard induction chemotherapy, those treated with azacitidine and venetoclax had superior overall survival and incidence of remission compared with patients who were treated with azacitidine alone. Read more.